secwatch.observer — SEC 8-K summary
======================================

Issuer:     TANDEM DIABETES CARE INC (TNDM)
CIK:        0001438133
Form:       8-K
Filed at:   2024-06-21T23:59:59+00:00
Accession:  0001438133-24-000166
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Tandem Diabetes appoints Jean-Claude Kyrillos as EVP, COO effective June 21, 2024
--------------------------------------------------------------------------------

- Kyrillos previously served as President of Diagnostics & Digital Solutions at Envista Holdings and held senior roles at Qualcomm Life, BD, and ResMed.
- Annual base salary set at $450,203.73; target bonus of 60% of base salary (0-200% payout range) under Cash Bonus Plan.
- Target long-term incentive of 400% of base salary in RSUs under the 2023 Long-Term Incentive Plan.
- Severance agreement provides 18 months base salary continuation and full equity acceleration upon qualifying termination within change-of-control window.
- Kyrillos holds a BA from Colgate University and an MBA from Harvard Business School.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438133/000143813324000166/0001438133-24-000166-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438133/000143813324000166/tndm-20240619.htm
  HTML page:      https://secwatch.observer/filing/0001438133-24-000166

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer